Medtronic announces new data shared on IN.PACT Admiral DCB
Medtronic announced new data shared on the IN.PACT Admiral drug-coated balloon in patients with peripheral artery disease in the superficial femoral and popliteal arteries. Outcomes from the IN.PACT DCB Paclitaxel Safety Analysis, an independent, patient-level survival analysis inclusive of all IN.PACT DCB clinical programs, were presented at the Leipzig Interventional Course in Leipzig, Germany. A manuscript detailing outcomes from the IN.PACT DCB Paclitaxel Safety analysis was also accepted and is in press with the Journal of the American College of Cardiology. At five years there was no statistically significant difference in all-cause mortality between the DCB and plain balloon angioplasty arms. Data found no correlation between paclitaxel dose and long-term survival. Patients treated in the DCB arm were classified by upper, mid, and lower dose ranges. Freedom from all-cause mortality based on Kaplan-Meier estimates was 91.7 percent in the upper range, 90.6 in the mid-range, and 90.0 percent in the lower range. Data demonstrated no difference in mean nominal dose of paclitaxel between overall survival in patients treated with DCB and those who died. Mean nominal paclitaxel doses were 11,829.8ug +/- 7,347.6ug and 11,419.6ug +/- 7,414.8ug respectively.